EE04432B1 - Substituted indolinones inhibit kinases and cyclin / CDK complexes - Google Patents

Substituted indolinones inhibit kinases and cyclin / CDK complexes

Info

Publication number
EE04432B1
EE04432B1 EEP200000598A EEP200000598A EE04432B1 EE 04432 B1 EE04432 B1 EE 04432B1 EE P200000598 A EEP200000598 A EE P200000598A EE P200000598 A EEP200000598 A EE P200000598A EE 04432 B1 EE04432 B1 EE 04432B1
Authority
EE
Estonia
Prior art keywords
cyclin
cdk complexes
inhibit kinases
substituted indolinones
indolinones
Prior art date
Application number
EEP200000598A
Other languages
Estonian (et)
Inventor
Heckel Armin
Walter Rainer
Grell Wolfgang
C. A. Van Meel Jacobus
Redemann Norbert
Original Assignee
Boehringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg
Publication of EE200000598A publication Critical patent/EE200000598A/en
Publication of EE04432B1 publication Critical patent/EE04432B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
EEP200000598A 1998-04-15 1999-04-10 Substituted indolinones inhibit kinases and cyclin / CDK complexes EE04432B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19816624A DE19816624A1 (en) 1998-04-15 1998-04-15 Novel substituted indolinones, their preparation and their use as pharmaceuticals
PCT/EP1999/002436 WO1999052869A1 (en) 1998-04-15 1999-04-10 Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes

Publications (2)

Publication Number Publication Date
EE200000598A EE200000598A (en) 2002-04-15
EE04432B1 true EE04432B1 (en) 2005-02-15

Family

ID=7864562

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000598A EE04432B1 (en) 1998-04-15 1999-04-10 Substituted indolinones inhibit kinases and cyclin / CDK complexes

Country Status (31)

Country Link
EP (1) EP1071665B1 (en)
JP (1) JP4015365B2 (en)
KR (1) KR100588250B1 (en)
CN (1) CN100338036C (en)
AR (1) AR015763A1 (en)
AT (1) ATE251138T1 (en)
AU (1) AU749829B2 (en)
BG (1) BG64443B1 (en)
BR (1) BR9909688A (en)
CA (1) CA2323111C (en)
CO (1) CO5011040A1 (en)
DE (2) DE19816624A1 (en)
DK (1) DK1071665T3 (en)
EA (1) EA003532B1 (en)
EE (1) EE04432B1 (en)
ES (1) ES2207209T3 (en)
HU (1) HUP0101568A3 (en)
ID (1) ID26420A (en)
IL (1) IL138036A0 (en)
MY (1) MY122357A (en)
NO (1) NO317298B1 (en)
NZ (1) NZ507967A (en)
PL (1) PL343314A1 (en)
PT (1) PT1071665E (en)
SK (1) SK283824B6 (en)
TR (1) TR200002980T2 (en)
TW (1) TW510897B (en)
UA (1) UA63009C2 (en)
WO (1) WO1999052869A1 (en)
YU (1) YU59800A (en)
ZA (1) ZA200004623B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
DE19924401A1 (en) * 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
CA2381821A1 (en) 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Substituted indolinones, their manufacture and their use as medicaments
UA75054C2 (en) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
JP3663382B2 (en) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド Pyrrole-substituted 2-indolinone protein kinase inhibitor
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
JP2003535847A (en) 2000-06-02 2003-12-02 スージェン・インコーポレーテッド Indolinone derivatives as protein kinase / phosphatase inhibitors
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
DE10117204A1 (en) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma Indolinones substituted in the 6-position, their preparation and their use as medicaments
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
CA2478156C (en) 2002-03-26 2011-02-15 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (en) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z- [1- (4- (N - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl- 2-indolinone monoethanesulfonate and its use as a medicament
DE10237423A1 (en) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound
JP4879492B2 (en) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド Kinase inhibitors for the treatment of diseases
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
UY28526A1 (en) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma GLUCOCORTICOID MIMETICS, METHODS OF PREPARATION PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME
CA2541059C (en) * 2003-10-03 2013-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescent probes for use in protein kinase inhibitor binding assay
DE102004012070A1 (en) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cycloalkyl-containing 5-acylindolinones, their preparation and their use as medicaments
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
CA2592514A1 (en) 2004-12-27 2006-07-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ES2348099T3 (en) * 2005-06-10 2010-11-30 Merck Patent Gmbh OXINDOLS AS KINASE INHIBITORS.
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
AU2007329548A1 (en) 2006-12-06 2008-06-12 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP2300472B1 (en) 2008-06-06 2012-01-18 Boehringer Ingelheim International GmbH Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
WO2013074459A1 (en) * 2011-11-14 2013-05-23 Ligand Pharmaceuticals, Inc. Methods and compositions associated with the granulocyte colony-stimulating factor receptor
US9962370B2 (en) * 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
CN107033064B (en) * 2017-04-28 2019-07-09 西安医学院 A kind of 3- (morpholine replaces fragrant imido grpup) Benzazole compounds and its preparation method and application
CN111285872B (en) * 2018-12-06 2022-05-17 北京志健金瑞生物医药科技有限公司 Indole-2-ketone derivative and preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19824922A1 (en) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
UA75054C2 (en) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament

Also Published As

Publication number Publication date
NO20005151D0 (en) 2000-10-13
EP1071665A1 (en) 2001-01-31
MY122357A (en) 2006-04-29
AU749829B2 (en) 2002-07-04
TR200002980T2 (en) 2001-02-21
NZ507967A (en) 2003-04-29
AU3814999A (en) 1999-11-01
ID26420A (en) 2000-12-21
KR100588250B1 (en) 2006-06-13
NO317298B1 (en) 2004-10-04
CN1297438A (en) 2001-05-30
JP2002511449A (en) 2002-04-16
ES2207209T3 (en) 2004-05-16
AR015763A1 (en) 2001-05-16
HUP0101568A2 (en) 2001-09-28
EE200000598A (en) 2002-04-15
EP1071665B1 (en) 2003-10-01
ZA200004623B (en) 2001-05-30
BG104813A (en) 2001-08-31
EA003532B1 (en) 2003-06-26
ATE251138T1 (en) 2003-10-15
PL343314A1 (en) 2001-08-13
DE19816624A1 (en) 1999-10-21
TW510897B (en) 2002-11-21
DE59907199D1 (en) 2003-11-06
CN100338036C (en) 2007-09-19
BR9909688A (en) 2000-12-19
CA2323111C (en) 2009-09-15
IL138036A0 (en) 2001-10-31
HUP0101568A3 (en) 2002-12-28
YU59800A (en) 2003-04-30
WO1999052869A1 (en) 1999-10-21
SK283824B6 (en) 2004-02-03
UA63009C2 (en) 2004-01-15
BG64443B1 (en) 2005-02-28
EA200001021A1 (en) 2001-06-25
NO20005151L (en) 2000-10-13
SK15132000A3 (en) 2001-03-12
KR20010042731A (en) 2001-05-25
CO5011040A1 (en) 2001-02-28
PT1071665E (en) 2004-02-27
CA2323111A1 (en) 1999-10-21
DK1071665T3 (en) 2004-01-05
JP4015365B2 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
EE200000598A (en) Substituted indolinones inhibit kinases and cyclin / CDK complexes
DK1115704T3 (en) Substituted indolinones with inhibitory effect for various kinases and cyclin / CDK complexes
EE200000622A (en) Transmitter-receiver for GMSK and offset-QAM
DK0877845T3 (en) Reversible inserts lock
PT904774E (en) RESORCINOL DERIVATIVES
DE69916691D1 (en) Pacemaker
ID26130A (en) IMPROVEMENTS IN MEDICAL INTRODUCTION TOOLS
FI981653L (en) Method and arrangement for managing connections
FI982525A0 (en) Security arrangement
NO20003154D0 (en) Insert the plug
DE59810269D1 (en) Self-calibrating rate-adaptive pacemaker
DE69906152D1 (en) 4-ALKENYL (AND ALKINYL) OXOINDOLE AS INHIBITORS CYCLINE-DEPENDENT KINASES, ESPECIALLY CDK2
EE200100347A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
NO20010200D0 (en) Organic phosphorus compounds and their use
MA26613A1 (en) SUBSTITUTED PYRROLES
DE69926591D1 (en) Fail-safe defibrillator
FR2776660B1 (en) DIAZEPINO-INDOLES OF PHOSPHODIESTERASES IV
FR2774599B1 (en) POULTICE
ZA200102260B (en) Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes.
ATA15398A (en) LOCKING LID
DE69920224D1 (en) Urea derivatives for pain relief
DE59911871D1 (en) Dual-chamber pacemakers
DE59813079D1 (en) Milling tooth for earthworking
DE69803818D1 (en) connector lock
DE59900924D1 (en) Self-calibrating rate-adaptive pacemaker

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

MM4A Lapsed by not paying the annual fees

Effective date: 20070410